Company: Dr. Reddy's Laboratories Ltd. Category: Broker Research


DRRD launched gSuboxone sublingual films post approval in all the four dosage strengths from USFDA
June 15, 2018, 3:59 p.m.
Publisher: plindia.com

Motilal Oswal stays Neutral on Dr Reddy’s Labs
June 15, 2018, 12:23 p.m.
Publisher: motilaloswal.com

We believe the stock will remain range bound until there is more visibility on key launches in the US (including Aloxi, Nuvaring, Soboxone, and Copaxone 20 and 40mg). Maintain Neutral with a target price of...
Oct. 5, 2017, 5:16 p.m.

Dr Reddy’s Labs: Maintain Neutral with a target price of Rs.2400
Oct. 5, 2017, 10:19 a.m.


Dr Reddy’s Laboratories (DRRD) has been under dark clouds - delays in approvals, regulatory overhangs and intensifying competition, culminating in a sharp 46% dip in FY17 earnings.
Sept. 21, 2017, 12:38 p.m.
Publisher: dsij.in

Motilal Oswal recommend 'Neutral' on Dr.Reddy's Labs due to no revenue impact post no supply to EU
Sept. 11, 2017, 12:01 p.m.

Dr. Reddy’s Laboratories: Company Update - Nirmal Bang
Sept. 5, 2017, 12:40 p.m.
Author : Nirmal Bang | Publisher: nirmalbang.com

Dr. Reddy's Labs: Maintain Neutral, says Motilal Oswal
Sept. 4, 2017, 9:30 a.m.

  • 1
-->